Articles tagged with Alzheimer Disease
A recent study published in JAMA Neurology investigated the association between glucose intolerance and insulin resistance with brain β-amyloid burden. The research found no significant link between these conditions and AD pathology. Long-term therapeutic trials may be necessary to further elucidate this issue.
A study at Columbia University Irving Medical Center identifies key molecular pathways leading to late-onset Alzheimer's disease. The research highlights several new potential drug targets, including SV2A and RFN219, which are involved in the processing and trafficking of amyloid precursor protein.
A recent study conducted at the University of Eastern Finland found that early diagnosis and treatment of Alzheimer's disease can significantly reduce psychological and behavioral symptoms. Persons with a very mild Alzheimer's disease diagnosed at an early stage are better able to manage their daily activities than those diagnosed at a...
A study by Rhode Island Hospital researchers found that caregivers of people with Alzheimer's and other forms of dementia can benefit from tailored interventions. The factors contributing to caregiver burden include direct impact on their lives, feelings of guilt, frustration, or embarrassment.
New data presents promising evidence for novel therapies targeting hippocampal neurogenesis and adrenergic receptors in Alzheimer's patients. Computerized cognitive tests show potential in improving attention and memory in Parkinson's disease dementia and dementia with Lewy Bodies.
Jason H. Moore, Professor at Dartmouth College, has been recognized for his expertise in translational bioinformatics and personalized medicine. He presented his research on Alzheimer's disease at the Third Indonesian-American Kavli Frontiers of Science Symposium.
Eva-Maria and Eckhard Mandelkow have made significant progress in understanding the role of tau protein in Alzheimer's disease. Their findings suggest that modifications to normal tau proteins can destroy synapses and lead to cognitive decline, offering a potential target for therapy.
A study found that individuals with an uncommon genetic risk for Alzheimer's disease did not experience increased anxiety or distress after learning their genetic risk. Instead, they took proactive measures such as exercising and following a healthy diet to mitigate their risk of developing Alzheimer's disease.
Researchers found a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated patients with the ApoE4 genotype. Biomarker analyses also showed increases in anti-oligomer and anti-fibril antibodies in IVIG-treated patients.
Researchers found that amyloid plaque accumulation in the temporal lobe, rather than total amount, is associated with cognitive decline. This pattern of progression may serve as a more powerful biomarker for early detection of Alzheimer's disease.
A study published in Neural Regeneration Research found that paeonol, a natural compound, attenuates inflammation-mediated neurotoxicity and microglial activation. This suggests that paeonol may be effective in treating neurodegenerative diseases such as Alzheimer's and Parkinson's.
Researchers discovered that nearly half of participants with mild to moderate Alzheimer's disease had impaired glucose tolerance or diabetes. The resveratrol study aims to investigate the link between glucose levels and Alzheimer's risk, raising potential for earlier diagnosis and prevention strategies.
The BrightFocus Foundation has awarded $7.2 million in grants to 53 scientists conducting research on Alzheimer's, glaucoma, and macular degeneration. The funded projects focus on imaging technology, gene therapy, and cell regeneration to better understand disease development and potential new therapies.
A large study found that people with Alzheimer's disease had a cut in half risk of developing cancer, and those with cancer had a reduced risk of developing Alzheimer's by 35%. The researchers controlled for life expectancy to confirm the findings.
A recent Penn study found a significant association between cerebrovascular disease and dementia, particularly in younger patients with Alzheimer's disease. The researchers suggest that early management of vascular risk factors and healthy lifestyles may delay or prevent the onset of dementia due to Alzheimer's and Parkinson's disease.
A recent study published in the American Journal of Neuroradiology found that women with mild cognitive impairment experience higher rates of cognitive decline than men, while all women exhibit greater regional brain loss over time. The study's authors suggest that hormonal differences may play a role in these findings.
Patients with epilepsy and mild cognitive impairment (aMCI) showed earlier cognitive decline than those without epilepsy. Epilepsy increases the risk of seizures and accelerates symptoms in Alzheimer's disease (AD). Identifying and treating epilepsy could improve clinical outcomes for patients.
Researchers have discovered that a single protein, alpha-synuclein, can exist in two different structural shapes, or 'strains', which promote misfolding of other disease proteins commonly found in Alzheimer's and Parkinson's. This finding has significant implications for the development of therapies for neurodegenerative diseases.
Researchers discovered a common biochemical thread to multiple diseases and found that CD36 draws soluble particles inside cells, triggering an inflammatory response. Blocking the CD36 receptor reduces inflammation and improves symptoms in mice with atherosclerosis.
Researchers discovered that Alzheimer's drugs designed to target amyloid plaques are ineffective against small Aβ clumps called oligomers. Future studies aim to develop new drugs specifically targeting these oligomers to potentially treat the disease.
Researchers identified a key role for Scara1 in clearing amyloid beta from the brain, which may lead to a new therapeutic approach for Alzheimer's. In mouse models, Scara1 deficiency accelerated A-beta deposition and death, while upregulation enhanced clearance.
Scientists identify glymphatic system as a potentially powerful tool for treating neurological disorders like Alzheimer's disease. The system is responsible for removing waste from the brain, and its dysfunction may contribute to these conditions.
Researchers identify amylin protein deposits in Alzheimer's disease brains, linking it to age-related dementia and Alzheimer's. Amylin accumulation may be therapeutic target for drug development.
A new class of experimental drugs has shown promise in preventing early memory loss in Alzheimer's disease by targeting a brain enzyme. The compound, MW108, halted memory loss and fixed damaged communication among brain cells in a mouse model of the disease.
Researchers at UCSB have discovered a new potential target in the fight against Alzheimer's and other neurodegenerative diseases by exploring the possibility of inhibiting hyperphosphorylated tau. The study found that small molecular kinase inhibitors can efficiently reduce tau phosphorylation and exert a neuroprotective effect, restor...
Researchers at Columbia University Medical Center have found that caspase-2 is a key regulator of cognitive decline in Alzheimer's disease. The study suggests that inhibiting this protein could prevent neuronal damage and cognitive decline associated with the disease.
Researchers found that a protein controlling Alzheimer's disease also affects muscle development and coordination in mice. The study suggests that inhibitors of this protein, currently being tested for Alzheimer's treatment, might disrupt muscle spindle formation and impair movement.
Researchers found that interactions between tau and amyloid-beta proteins in the brain may worsen Alzheimer's disease progression. The study identified the presence of these protein complexes in human brain tissue and mouse brains with Alzheimer's, suggesting a potential key to understanding the disease.
Researchers found a striking resemblance between white matter brain abnormalities in concussion patients and those seen in early Alzheimer's dementia. The study suggests that the true problem facing concussion patients may be their brain's response to injury, rather than the injury itself.
A study by McGill University researchers found that blocking the activity of a specific receptor can reverse memory pathology and improve cerebrovascular function in mice with advanced Alzheimer's disease. The treatment also reduced toxic amyloid-beta peptide levels, which contribute to neuronal and vascular dysfunction.
Researchers discovered unique copy-number variants (CNVs) in genes important to neuronal function, affecting 10 families with early-onset Alzheimer's. CNVs were found to be associated with novel gene mutations not previously linked to the disease.
A study found that diet high in saturated fat increased LD αβ levels, while diet low in saturated fat decreased these fractions. The study suggests that lipidation states of apolipoproteins and amyloid peptides may play a role in AD pathological processes.
Researchers at Sanford-Burnham Medical Research Institute developed a new drug, NitroMemantine, that boosts brain synapses lost in Alzheimer's disease. The drug restores synaptic connections between nerve cells, offering new hope for early and late-stage Alzheimer's patients.
Researchers at The Mount Sinai Medical Center found that commonly prescribed medications can either block or enhance beta-amyloid accumulation in the brain. Treatment with certain drugs has been shown to significantly reduce amyloid plaques and neurodegeneration in mice.
Researchers found that people with inherited Alzheimer's disease produce 20% more of a specific form of amyloid beta, known as amyloid beta 42. Additionally, the protein drops out of cerebrospinal fluid more quickly in mutation carriers, suggesting a link to brain amyloid plaques.
Researchers found hypometabolism in brain regions associated with Alzheimer's disease, even in cognitively normal subjects with amyloid plaque. This association suggests a potential early indicator of Alzheimer's disease before dementia sets in.
Researchers found that HDAC3 is essential for DNA replication in hematopoietic progenitor cells and plays a critical role in Alzheimer's disease pathogenesis by binding to the cellular protein FCγRIIb, which activates cell stress and death pathways. The study also identified a link between FCγRIIb and memory impairment in AD patients.
China experiences a significant increase in Alzheimer's cases from 1.93m in 1990 to 5.69m in 2010, highlighting the need for improved awareness and resources to tackle this growing public health issue. The study suggests that global estimates of Alzheimer's disease may need revision upwards by at least 5 million cases, or almost 20%.
A nationwide study in Sweden found that people with Alzheimer's disease taking cholinesterase inhibitors have a 36% lower risk of death, 38% lower risk of heart attack, and 26% lower risk of cardiovascular deaths compared to non-users. Patients on the highest recommended doses had the lowest risk of heart attack or death.
Tel Aviv University researchers used a method to modify the levels of the protein tomosyn in the mouse hippocampus, leading to a decline in learning and memorization abilities. The study suggests that adjusting tomosyn levels may help increase cognition and combat memory loss in Alzheimer's patients.
Researchers at Araclon Biotech have developed a blood test to measure beta amyloid peptides, which are associated with Alzheimer's disease. The test shows a high level of association between peptide levels and the disease, suggesting a potential biomarker for early diagnosis.
Research published in The Journal of Nuclear Medicine found that highly educated pre-Alzheimer's patients exhibit increased neural reserve and compensation, leading to better coping mechanisms. This suggests that education level plays a crucial role in determining cognitive reserve against the disease.
A new study found that exposure to general anaesthesia may increase the risk of dementia in elderly patients by 35%. The research analyzed data from a prospective population-based cohort and found that participants who received general anaesthetics were more likely to develop dementia. This increased risk was significant even after adj...
Researchers analyzed cerebrospinal fluid and plasma samples from patients with no cognitive decline, mild cognitive impairment, and Alzheimer's disease. They detected significant changes in metabolic pathways related to mitochondrial function, validating blood as a reliable source for biomarker development.
A team of researchers at Lund University has identified the molecular mechanism behind the formation of Alzheimer's disease-causing plaques. The discovery reveals a self-perpetuating and autocatalytic process that creates cell-killing formations, potentially paving the way for new treatments targeting early stages of the disease.
Scientists at the University of Liverpool and Callaghan Innovation have developed a new chemical approach to harness the natural ability of complex sugars to treat Alzheimer's disease. They produced a library of sugars called heparan sulphates, which can inhibit an enzyme that creates small proteins in the brain causing memory loss.
A study by University at Buffalo researchers has identified a novel function of the protein presenilin in controlling the speed of molecular motors along neuronal highways. This regulation may prevent deadly blockages in neurodegenerative diseases like Alzheimer's, offering hope for new treatments.
Researchers suggest targeting APPL protein for new Alzheimer's drugs, as it ensures optimal communication between brain cells. This approach may be more effective than solely focusing on breaking down Amyloid beta.
Researchers recommend against testing bexarotene on patients due to inconsistent results in various animal test models. The study highlights the importance of rigorous scientific evaluation and reproducibility.
Researchers found that an anti-cancer drug, bexarotene, did not reduce amyloid plaques in the brains of mice, despite initial claims of its effectiveness in reversing Alzheimer's-like symptoms. The study suggests that further research is needed to understand the nuances of this potential treatment.
Researchers at Pitt Public Health have found that an anti-cancer drug, bexarotene, significantly improves cognitive deficits in mice with Alzheimer's gene mutations. The study suggests a possible new therapeutic treatment for Alzheimer's disease, although the exact mechanism of action remains unclear.
Despite promising initial results, a breakthrough treatment for Alzheimer's disease did not show any reduction in plaque burden after extensive testing. Three independent research groups failed to confirm the efficacy of bexarotene in reversing beta amyloid plaques.
Scientists at USC have found a class of drugs, TSPO ligands, that can reduce measures of pathology and improve behavior in both young adult and aged mice with Alzheimer's Disease. The treatment showed promising results, including a significant decrease in symptoms and improvements in memory.
Scientists at Cambridge's Department of Chemistry have mapped the pathway that generates 'aberrant' forms of proteins, which are at the root of neurodegenerative conditions like Alzheimer's. The breakthrough opens up possibilities for a new generation of targeted drugs and earlier diagnosis of neurological disorders.
A new study found a link between sleep-disordered breathing (SDB) and Alzheimer's disease risk factors in cognitively normal elderly patients. Lean SDB patients showed biomarkers of AD risk, including increased P-Tau and T-Tau levels, glucose hypometabolism, and hippocampal atrophy.
Drs. Yueming Li and Lennart Mucke have made significant contributions to understanding Alzheimer's disease mechanisms, identifying underlying processes that impair cognitive functions. Their work has led to promising new directions for treatment, including targeting gamma-secretase activity and modulating protein interactions.
A study published in Neurology found that individuals with skin cancer had a nearly 80% lower risk of developing Alzheimer's disease. The researchers suggest physical activity and biological factors as possible explanations for this link.
Researchers found that parts of the prefrontal cortex take over when the hippocampus, a key learning and memory center, is disabled. The breakthrough discovery could potentially help develop new treatments for Alzheimer's disease, stroke, and other conditions involving brain damage.
Researchers have identified biomarkers that can predict cognitive impairment up to 7.5 years before symptoms develop, with sex, age, and race also playing a role in the prediction. The findings provide valuable evidence for the development of new treatments targeting Alzheimer's disease before symptoms appear.
ADAM10, a protein that prevents β-amyloid formation, is removed from synapses through association with AP2. This study identifies pathological mechanisms controlling protein localization at the synapse in Alzheimer's disease.